The transthyretin amyloidosis treatment market, valued at USD 7.81 billion in 2024, is projected to surge to USD 17.80 billion by 2032, expanding at a notable CAGR of 14.64% from 2025 to 2032. This growth is fueled by a combination of increasing disease awareness, emerging therapies, favorable regulatory support, and significant strides in genetic diagnostics and personalized medicine.
Market Dynamics Driving the Transthyretin Amyloidosis Treatment Market
The transthyretin amyloidosis treatment market is experiencing rapid evolution driven by rising diagnosis rates and innovation in targeted therapies. ATTR amyloidosis, once considered an underdiagnosed condition, is now more widely recognized due to advances in imaging, genetic testing, and broader physician awareness. Pharmaceutical innovations, including the development of RNA interference (RNAi) therapies and TTR stabilizers, are addressing unmet medical needs for both hereditary and wild-type transthyretin amyloidosis.
Stay Informed on Key Market Changes: Get a Sample Report! https://www.snsinsider.com/sample-request/6932
Despite positive developments, challenges persist. High treatment costs, delayed diagnosis in emerging economies, and limited patient access to specialty therapies in low-resource settings pose barriers to widespread adoption. However, continued investment in clinical research and market access initiatives are anticipated to bridge these gaps over time.
Transthyretin Amyloidosis Treatment Market Segmentation Analysis
By Therapy:
The transthyretin amyloidosis treatment market is dominated by targeted therapy options, notably Vyndaqel/Vyndamax (tafamidis), Onpattro (patisiran), Amvuttra (vutrisiran), Tegsedi (inotersen), and Wainua. These therapies offer disease-modifying benefits and have reshaped the treatment landscape for ATTR-PN and ATTR-CM.
Supportive therapies continue to play a critical role, particularly in regions where newer agents are either unavailable or unaffordable. The pipeline therapy segment is anticipated to witness exponential growth, with several investigational agents targeting both amyloid deposition and TTR gene expression.
By Type:
The transthyretin amyloidosis treatment market is segmented into ATTR with Polyneuropathy (ATTR-PN) and ATTR with Cardiomyopathy (ATTR-CM). ATTR-CM accounts for a significant portion of the market, driven by an aging population and improved detection rates of wild-type cases. ATTR-PN, however, is expected to experience strong growth due to expanded indications and patient advocacy efforts.
By Disease:
Within the disease category, hereditary transthyretin amyloidosis, especially with cardiomyopathy and polyneuropathy manifestations, remains a major revenue contributor to the transthyretin amyloidosis treatment market. The wild-type amyloidosis segment, historically overlooked, is gaining traction thanks to greater clinical awareness and emerging non-invasive diagnostics.
By Distribution Channel:
Hospital and specialty pharmacies dominate the transthyretin amyloidosis treatment market, reflecting the complexity of disease management and the need for specialist oversight. However, online pharmacies are beginning to emerge as a cost-effective and accessible channel in developed markets, particularly for maintenance therapy.
Accelerate Growth with Strategic Insights Enquiry on Report Now! https://www.snsinsider.com/enquiry/6932
Regional Insights into the Transthyretin Amyloidosis Treatment Market
North America continues to lead the transthyretin amyloidosis treatment market, with the United States accounting for the largest revenue share due to favorable reimbursement policies, advanced healthcare infrastructure, and the presence of key market players such as Alnylam Pharmaceuticals and Pfizer Inc. Canada and Mexico are also expanding their treatment capacities through public-private partnerships.
Europe holds the second-largest market share, with countries like Germany, France, the UK, and Spain investing heavily in rare disease research and patient care networks. The European Medicines Agency’s (EMA) support for orphan drugs has further accelerated regional growth.
Asia Pacific is poised for significant growth in the transthyretin amyloidosis treatment market, particularly in countries such as China, India, Japan, and South Korea. Rising healthcare spending, government-led rare disease frameworks, and increasing adoption of genetic testing are key growth drivers.
Middle East & Africa and Latin America represent emerging markets with moderate growth potential. Awareness campaigns and collaborations with global health organizations are paving the way for early diagnosis and access to innovative treatments in these regions.
Competitive Landscape of the Transthyretin Amyloidosis Treatment Market
The transthyretin amyloidosis treatment market is highly competitive and innovation-driven. Key players include:
- Alnylam Pharmaceuticals – pioneers of RNAi therapies such as Onpattro and Amvuttra.
- Pfizer Inc. – leading with tafamidis-based drugs Vyndaqel and Vyndamax for ATTR-CM.
- Ionis Pharmaceuticals – co-developer of Tegsedi and advancing antisense therapy platforms.
- BridgeBio Pharma and Eidos Therapeutics – working on next-generation TTR stabilizers.
- Prothena Corporation plc – exploring novel immunotherapies targeting amyloid deposits.
- Akcea Therapeutics, SOM Biotech, Alexion Pharmaceuticals, and AstraZeneca plc – actively pursuing pipeline developments and market expansion.
Strategic collaborations, licensing deals, and ongoing clinical trials are shaping the future of the transthyretin amyloidosis treatment market. Increasing competition is expected to benefit patients by broadening treatment options and potentially reducing costs.
Contact Our Analyst to Assist with Your Questions! https://www.snsinsider.com/request-analyst/6932
Outlook: A Promising but Challenging Road Ahead for the Transthyretin Amyloidosis Treatment Market
The transthyretin amyloidosis treatment market presents a dynamic and high-growth opportunity, driven by precision medicine, robust pipelines, and expanding global reach. However, realizing its full potential requires addressing systemic barriers such as affordability, diagnosis delays, and treatment access disparities.
As innovation continues to redefine clinical care for ATTR amyloidosis, stakeholders across the value chain—biotech companies, regulators, clinicians, and payers—must collaborate to ensure sustainable and equitable growth in the transthyretin amyloidosis treatment market.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
